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ABSTRACT 
Objective: A simple, selective and sensitive reverse-phase high-performance liquid chromatography (RP-HPLC) method to estimate repaglinide 
(REP) in rabbit plasma using rabeprazole (RAB) as an internal standard was developed and validated for various qualifications.  
Methods: The chromatographic separation was performed on C18 
Results: The retention times of REP and RAB were found at ~4.3 and 5.1 min respectively, with adequate system suitability parameters (theoretical 
plates ≥3619, tailing factor ≤1.38, resolution factor 2.37). The method has linearity over a concentration range of 10 to 1000 ng/ml (r
(2) analytical column (5 μ, 250×4.6 mm) using acetonitrile: 0.05% trifluoroacetic 
acid in water (55:45, v/v) as mobile phase at the flow rate of 1 ml/min. Validation of the analytical method was performed as per ICH guidelines.  
2
Conclusion: The developed RP-HPLC method for estimation of REP in rabbit plasma was developed. The method was found to be rapid, cost-
effective and accurate to estimate the REP from the sample matrix. The method can be a most useful tool for in vivo study of REP in the rabbit.  
=0.9987). The 
results of accuracy (≥98.17%), intra-, inter-day precision (≤2.9%), recovery (101.21±2.09%) and process efficiency (99.77±3.74%) found 
satisfactory with no matrix effect. The analyte in samples were found stable up to 6 h, 3 freeze-thaw cycles and not more than 2 mo corresponding 
to bench-top, short and long term stability studies respectively.  
Keywords: HPLC-UV, Repaglinide, Bioanalytical, Validation, Rabbit plasma 




Repaglinide (REP) is a novel carbomoxyl methyl benzoic acid 
derivative, also known as 2-ethoxy-4-[2-[[3-methyl-1-[2-
(lpiperidinyl)-phenyl] butyl] amino]-2-oxoethyl]-benzoic acid (fig. 
1) [1]. It is a novel short-acting secretagogue belongs to meglitinide 
class, used to regulate fasting as well as postprandial elevated blood 
glucose in patients under the treatment of type-II diabetes mellitus 
[2, 3]. It was understood from the literature that, REP reduces the 
hyperglycemia by stimulating pancreas through depolarization of β-
cells via K+ ATP channel blockade at plasma membrane, thereby ensue 
Ca2+influx through voltage-dependent channels, that triggers the 
Ca2+
To date, several analytical techniques have been reported to 
estimate REP from human plasma, involving competitive solid-phase 
enzyme immunoassay [6], high-performance liquid chromatography 
(HPLC) integrated with electrochemical [7], ultraviolet (UV) [8, 9], 
photodiode-array (PDA) [10], detectors. Gradient elution techniques 
for concurrent estimation of REP with other anti-diabetic agents 
from the biological matrix on HPLC using UV detection were 
reported [8, 9]. Furthermore, HPLC-tandem mass spectrometry 
(LC/MS/MS) methods were established to assess the REP from 
plasma and urine samples of human [10, 11], monkey [12], rat [13] 
and equine [14]. Though, Gandhimathi et al., Berecka et al., Joshi et 
al. and Soni et al. were reported HPLC methods to estimate the REP 
alone or combined with other drugs from pharmaceutical 
formulations but were not applied for biological samples [15-18]. 
However, all the above methods reported for REP estimation from 
biological matrix need of expensive instruments for gradient elution 
and for eluate detection, restrict the application of them in common 
research laboratories equipped with limited resources.  
dependent exocytosis of insulin-containing granules [2-5].  
The principle objective of the present study was to establish a 
simple, selective and precised reverse phase-HPLC (RP-HPLC) 
integrated with ultraviolet (UV) detection method to quantify REP in 
rabbit plasma using rabeprazole (RAB) as an internal standard (IS). 
Further, an attempt was done to validate the developed analytical 
method for essential qualifications like selectivity, linearity, 




Fig. 1: Chemical structure of REP 
 
MATERIALS AND METHODS 
Chemicals and reagents 
REP and RAB pure drug samples were acquired from KP Labs, 
Hyderabad, India. HPLC grade acetonitrile (ACN) and methanol were 
supplied by Rankem, Hyderabad, India. Trifluoroacetic acid (TFA) 
was supplied by SDFCL, Mumbai, India. HPLC grade water was used 
during the entire procedure. Heparin-coated blood sampling tubes 
were purchased from CML biotech (P) Ltd., Kerala, India. 
Instrumentation and chromatographic condition 
The HPLC (Shimadzu, Kyoto, Japan) system consists of a binary 
pump (LC-20AD), equipped with UV/Visible detector (SPD-A20), a 
Rheodyne injector port (7725i) with 20 μl loop volume and the data 
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acquisition was done by LC-solutions software. Weighing of 
materials was done with 0.1 mg precision balance (Denver 
Instruments, New York). Plasma samples processing was included 
vortex mixer, refrigerated centrifuge and deep freezer (Remi, India)  
The chromatograms were developed on an analytical column C18 
(2), 250×4.6 mm; 5 µ particle size (Luna®, Phenomenex) via 
isocratic elution by fixed composition of ACN:0.05% TFA in water 
(55:45, v/v) mixture as mobile phase, pumped with constant flow 
rate (1 ml/min) and 285 nm was set as detection wavelength for 
entire study. The composition of eluent was admixed freshly for 
total volume required, passed through a membrane filter (#0.45 µm) 
and degassed by ultrasonic bath sonication for 30 min precedent to 
each batch analysis. 
Standard solutions and quality control samples 
Individual primary stock solutions of REP and RAB (1 mg/ml) were 
prepared using methanol as solvent and kept at -20°C temperature 
to avoid decomposition of analyte on storage. The primary stock 
solution of REP was diluted appropriately with mobile phase 
mixture to obtain working standards (WS) in concentrations of 0.1, 
0.25, 0.5, 1, 2.5, 5 and 10 µg/ml, similarly, a single WS solution of IS 
(5 µg/ml) was also prepared for entire study. The standards for 
calibration (CS) were made by spiking of individual rabbit plasma 
(180 µl) with each WS solution of REP (20 µl) to result in (10, 25, 50, 
100, 250, 500 and 1000 ng/ml) plasma-drug mixture (200 µl) prior 
to analysis was done. Quality control (QC) standards of REP at 4 
different levels at lower limit of quantitation (LLOQ), low QC (LQC; 
3*LLOQ), medium QC (MQC; 50% of upper LOQ) and high QC (HQC; 
90% of upper LOQ) were independently made at concentration level 
of 10 ng/ml, 30 ng/ml, 500 ng/ml and 900 ng/ml respectively as like 
method described for CS.  
Extraction procedure  
Preparation of samples for injection to develop the chromatogram 
was done as per extraction procedure reported earlier by Yin et al. 
and Ma et al., with fewer modifications [19, 20]. To 200 µl rabbit 
plasma (blank/test/CS/QC) sample transferred in an eppendorf tube 
(2 ml) quadruple volume (800 ml) of ACN and 20 µl WS solution of 
RAB (5 µg/ml) was added as extraction reagent and IS respectively, 
capped and vortexed on a cyclomixture for 1 min. The mixture 
resulted was subjected to refrigerated centrifuge at 5000 g for 15 min 
at 4°C. The protein-free clear supernatant (500 µl) was shifted into a 
fresh eppendorf tube (1 ml) and evaporated to dryness in a vacuum 
concentrator. Reconstitution of the residue was done with mobile 
phase mixture (100 µl), capped, vortexed for a min and centrifuged 
again at 5000 g for 15 min at refrigerated condition (4°C). The 
particle-free clear supernatant (20 µl) was allowed to inject into the 
HPLC column to develop chromatogram.  
Method validation  
The validation approach is essential to demonstrate the competency 
of an analytical method for its purpose intended. The validation of 
the analytical method was conducted for essential qualifications like 
selectivity, linearity, accuracy, precision, LLOQ, matrix effect, 
recovery, performance of the method and stability of analyte were 
studied in accordance with guidelines of International Conference 
on Harmonization (ICH) and Food and Drug Administration (FDA) 
guidelines for bioanalytical method validation [21, 22]. 
Selectivity  
The blank chromatograms of plasma sample (n=3) were examined 
for probable interfering peaks at the detection time of REP and IS. In 
addition, chromatograms developed for rabbit plasma (n=3) spiked 
with IS alone and chromatograms of plasma spiked with both REP 
and IS were carefully examined for peak deriving and for significant 
interfering of each on other [22]. 
Linearity, range and lower limit of quantitation  
Linearity was measured through (1/x2) weighed linear regression 
equation (mean r2; n=5) of calibration graph plotted employing 
seven nonzero concentrations of REP (between range 10 to 1000 
ng/ml) spiked in rabbit plasma samples verses corresponding peak 
area ratio of REP:IS measured. Acceptance of the calibration curve 
was done when it passes good coefficient of correlation (r2≥0.98) 
and/or estimated precision (percentage coefficient of variation 
(%CV)) of CS fall within accepted limits (LLOQ: ±20%w/w and for 
all other CS levels within±15%w/w of theoretical/nominal 
concentration). LLOQ was defined as the least concentration of 
analyte present in plasma sample that could be determined with 
minimum accuracy (80% to 120%w/w) and precision (%CV) not 
more than (NMT) 20%w/w [10, 22].  
Accuracy and precision  
Accuracy (percentage relative error (%RE)) is the measure to which 
estimated value conforms to the theoretical/nominal amount of 
analyte exists in the sample matrix, was studied in 5 replicates of 4 
QC levels (LLOQ: 10, LQC: 30, MQC: 500 and HQC: 900 ng/ml) 
estimated against freshly constructed calibration curve (10 to 1000 
µg/ml). The assay of QC levels was repeated in 3 separate runs 
within a day and in 3 distinct days to determine intra-and inter-day 
precision (%CV) respectively. The acceptance limit for accuracy as 
well as precision was set as NMT±20%w/w for LLOQ and for all 
other QC level is NMT±15%w/w [22, 25].  
Matrix effect (ME), extraction efficiency (EE) and process 
efficiency (PE)  
All these parameters were studied using 3 sets of samples at 3 
individual QC levels (LQC: 30, MQC: 500 and HQC: 900 ng/ml) along 
with IS in triplicate. Set 1: QC levels prepared in methanol, set 2: QC 
levels spiked into liquid extracts of blank plasma and set 3: samples 
extracted from plasma spiked with QC levels. The ME was 
determined by relating the assay of set 2 with set 1; recovery was 
estimated by comparing set 3 with set 2 and PE was calculated by 
comparing set 3 with set 1. The EE was assessed from percentage 
recovery should be consistent rather than high value [22, 23]. 
Stability studies  
Stability of an analyte in the sample matrix is dependent on storage 
conditions and duration, chemical properties of an analyte and the 
matrix. Stability of REP in sample matrix was determined in triplicate, 
by assay of QC samples at 2 levels (LQC: 30 and HQC: 900 ng/ml) in all 
types of study. In bench-top stability study, the integrity of the REP 
and IS in wet state (blood and reconstituted sample) and dry state 
(extracted residue for reconstitution) samples were studied separately 
up to the average working period (6 h). Stress-induced stability was 
assessed by subjecting the QC (plasma) samples for 3 freeze-thawing 
(-25°C to 4°C) in a frequency of 1 cycle per day, in that the samples 
were kept at least 18-20 h in frozen state and 4-6 h thawing state in 
each cycle. The frozen QC samples were slowly thawed to room 
temperature at the end of each cycle and assayed to study the 
precision. In assessing long term stability, assay of the stored QC 
samples (-20°C) was done after thawing the samples to room 
temperature in order to determine the precision by end of 0, 1st, 2nd 
and 3rd
RESULTS  
 months. In all type of stability studies 0 time/0 cycle samples 
were kept as control and to which other samples were compared to 
assess the significance of difference by one way ANOVA [22-27].  
Statistical analysis  
All the results of assay, validation parameters and in vivo animal 
pharmacokinetic parameters were expressed in mean±SD, %CV and 
%RE. Statistical significance of variations was studied by one way 
ANOVA done by data analysis tool pack, Microsoft excel® (2007).  
Optimization of chromatographic condition  
The chromatographic separation and elution of analyte was done by 
mobile phase consisting of ACN:0.05% TFA in water (55:45, v/v) in 
reverse phase analytical column (250×4.6 mm; 5 µ particle size). The 
retention times (Rts) of REP and IS were found as ~4.3 and 5.1 min 
respectively. The system suitability parameters of the method were 
calculated as follows: theoretical plates for REP and IS were found as 
4764 and 3619 respectively. Tailing factor was found as 1.16 and 
1.38 for REP and IS respectively and the resolution between two 
drugs was found as 2.37. 
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Fig. 2: Chromatograms of (A) blank plasma, (B) rabbit plasma spiked with 500 ng/ml concentration of REP and IS, (C) Plasma sample 




The chromatogram of blank rabbit plasma sample (fig. 2. A) was 
compared with the chromatogram developed for rabbit plasma 
spiked with REP and IS (fig. 2. B). Further, the chromatogram of 
rabbit plasma sample collected at 1 h after 4 mg oral dosing of REP 
with spiked IS was illustrated in fig. 2. C. 
Linearity, range and lower limit of quantitation  
The linear regression equation of calibration curve plotted was 
resulted as Y=1.415X+0.0022 with r2
Accuracy and precision  
 value of 0.9987 and the 
linearity was found as high in between concentration range of 10 to 
1000 ng/ml. The LOD and LOQ value calculated from the regression 
equation of the calibration curve was found as 1.73 ng/ml and 5.23 
ng/ml respectively. The practical LLOQ of REP in rabbit plasma 
sample was accepted as 10 ng/ml.  
The accuracy and precision were expressed as %RE and %CV 
(table 1). The assay results studied for accuracy were varied 
between 98.17±2.71%w/w to 101.39±2.35%w/w, with %RE was 
ranged from -1.82%w/w to 1.39%w/w. The result of intra-day 
precision (%CV) was found between 0.65%w/w to 2.9%w/w and 
the inter-day precision was found in the range of 0.49%w/w to 
2.76%w/w. 
 
Table 1: Results of accuracy and precision study (n=5) 
Conc. spiked (ng/ml) Assay (%w/w) SD (%w/w) RE (%w/w) Conc. Found (ng/ml) SD (ng/ml) CV (%w/w) 
Intra Day 
10 101.02 2.93 1.02 10.1 0.29 2.9 
30 100.53 0.65 0.53 30.16 0.19 0.65 
500 99.72 2.19 -0.28 498.6 10.96 2.19 
900 98.73 2.2 -1.28 888.53 19.84 2.23 
Inter Day 
10 101.39 2.35 1.39 10.14 0.24 2.32 
30 100.68 0.49 0.68 30.2 0.15 0.49 
500 98.17 2.71 -1.82 490.88 13.56 2.76 
900 99.73 1.39 -0.27 897.61 12.54 1.39 
 
Matrix effect (ME), extraction efficiency (EE) and process 
efficiency (PE) 
The results of ME, EE and PE were determined by relating the assay 
of paired samples as described in the methods, was shown in table 2. 
All these three parameters were studied at QC levels 30, 500 and 
900 ng/ml in triplicates and the mean results determined for ME 
was 98.61±3.95, EE was 101.21±2.09 and PE was 99.77±3.74 % 
w/w.
  
Table 2: Results of matrix effect, extraction efficiency and process efficiency 
Drug conc. (ng/ml) Assay of sample ME* EE* PE* * 
Methanol Unextracted Extracted 
30 101.46±3.24 99.26±1.53 101.87±4.03 97.89±3.01 102.61±2.43 100.44±4.06 
50 99.67±5.16 98.53±2.14 99.73±1.92 99.1±6.99 101.24±2.15 100.24±5.47 
900 100.93±2.49 99.74±2.48 99.52±2.06 98.84±2.13 99.76±0.72 98.63±2.52 
Mean** 100.68 99.17 100.37 98.61 101.21 99.77 
%RSD** 3.39 1.88 2.7 3.95 2.09 3.74 
*All the results represented as mean±SD (n=3); **All the results represented as mean±SD (n=9) 
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Stability studies  
The bench-top stability study for the whole blood sample, dried and 
reconstituted samples after extraction was performed at 2 QC levels 
in triplicates and the results were shown in table 3. The results of 
stress-induced (freeze-thaw) and long term stability study (storing 
at -20 °C) were reported in table 4. 
  
Table 3: Results of bench top stability study after 6 h (n=3) 
QC Level Conc. (ng/ml) %Accuracy %RSD p-value 
blood 
LQC 30 101.74 5.85 0.92 
HQC 900 99.85 4.43 0.83 
Reconstututed 
LQC 30 102.6 2.14 0.17 
HQC 900 103.73 4.48 0.56 
Dry state 
LQC 30 100.2 3.73 0.85 
HQC 900 99.62 4.08 0.97 
 
Table 4: Results of short term and long term stability study (n=3) 
Short term (Stress induced) stability Long term stability 
QC Level Conc. (ng/ml) %Accuracy  % CV p-value %Accuracy  % CV p-value 
Cycle 0 0 Mo 
LQC 30 99.89 3.66 - 101.02 4.57 - 
HQC 900 100.37 1.75 - 100.91 2.75 - 
Cycle 1 1 Mo 
LQC 30 99.31 10.94 0.93 98.76 5.66 0.62 
HQC 900 95.53 8.91 0.41 99.79 3.03 0.66 
Cycle 2 2 Mo 
LQC 30 98.99 9.22 0.88 97.72 6.29 0.49 
HQC 900 98.2 7.05 0.63 95.45 5.53 0.19 
Cycle 3 3 Mo 
LQC 30 99.81 9.74 0.99 72.43 15.5 0.015 
HQC 900 98.06 10.93 0.73 69.64 17.24 0.012 
 
DISCUSSION 
The chromatographic condition was optimized for bio-analysis of 
REP in rabbit plasma using RAB as IS on RP-HPLC consisting with UV 
detection. In this process, several compositions between ACN and 
TFA (0.05% v/v in water) were tried as eluent to develop the 
chromatogram. Increased proportion of ACN in the mobile phase 
resulted in faster elution but the peaks of REP and IS were not 
completely separated. Reduction of ACN proportion in the mobile 
phase resulted tailing of peaks and it was found that mixture of 
ACN:0.05% TFA in water (55:45, v/v) as optimum mobile phase 
composition by which the REP peak clearly resolved from IS peak 
and solvent fronts. In order to develop a liquid-liquid extraction 
method, various solvents (ACN, Methanol, Dichloromethane and 
ethyl acetate) were used for extraction of REP and IS from plasma 
samples, among that ACN found to be most efficient than all others. 
This method was simple and efficient in the extraction of analyte and 
chromatogram developing when compared to earlier reported 
methods by Venkatesh et al. and Ruzilawati et al. [9, 10]. The system 
suitability parameters: theoretical plates (>3000), Tailing factor (<2) 
and resolution (>2) for the developed HPLC method were 
satisfactory to meet the ICH guidelines [21].  
The chromatogram of blank rabbit plasma sample was compared 
with the chromatogram developed for rabbit plasma spiked with 
REP and IS. No significant endogenous noise peaks around the Rts of 
REP and IS were found in chromatogram of blank plasma sample, 
justifies the selectivity of this analytical method. The calibration 
curve plotted using plasma concentration of REP (X) versus mean 
peak area ratio of REP:IS of triplicates (Y) has high linear 
(r2
The bench-top stability was studied to find the influence of the 
maximum processing time on the integrity of analyte in the matrix. The 
REP is proved to be stable in the wet state as well as dry state samples 
during an average bench-top working period (6 h). Also, the chemical 
stability of REP in plasma was confirmed at the end of 3 stress cycles 
applied (p≥0.73) and significant stability of analyte was retained in the 
plasma up to 2 mo (p≥0.19) during storage at -20°C, beyond that the 
integrity of analyte in the sample matrix was insignificant (p≤0.015).  
=0.9987) with acceptable variability (≤9.8%) in the selected 
concentration range indicates the sensitivity of the method as good. 
All the results of accuracy (%RE) and Precision (%CV) were found 
less than ±1.82%w/w and ±2.9%w/w respectively were complied 
with the official guidelines (%RE and %CV NMT±20%w/w for LLOQ 
and for other QC levels NMT±15%w/w) confirms the method’s 
accuracy and precision in estimation of analyte. The recovery of REP 
from plasma samples done by liquid extraction using ACN, shown 
better and consistent EE (99.76 to 102.61%w/w) than earlier 
reported by Venkatesh et al. (92.37 to 106.50%w/w) [8]. 
CONCLUSION 
A simple and selective RP-HPLC-UV method to estimate REP from 
rabbit plasma using RAB as an IS was developed and validated for 
various qualifications per ICH and FDA guidelines. The method is 
selective to estimate REP from the sample matrix, has good linearity, 
accuracy, precision and stability over the therapeutic range. The liquid 
extraction procedure used in this method was simple, reproducible 
with good extraction efficiency and process efficiency. The method 
could be applied to estimate the plasma concentration of REP after the 
suitable route of administration in New Zealand white rabbit to study 
the in vivo pharmacokinetics of REP from the dosage forms.  
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